Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 656.00p 652.00p 660.00p - - - 4,194 09:05:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 251.00

International Biotechnol... Share Discussion Threads

Showing 176 to 194 of 500 messages
Chat Pages: Latest  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
30/4/2010
11:09
The Board of International Biotechnology Trust plc (the "Company") notes that Gold Medal Acquisitions UK Limited has made a bid for the AIM listed company Fulcrum Pharma Plc (Ticker: LON:FUL). The Company has committed up to £1.3m to the funding of a new investment in Gold Medal Acquisitions UK limited were it to be successful in its bid.
davebowler
21/4/2010
12:35
http://www.internationalbiotrust.com/reports/IBTInterim2010.pdf
davebowler
17/4/2010
20:19
From the Times; IBT Vectura, Vernalis, and now Antisoma - the roster of British biotechnology stocks to have disappointed investors grows by the day. Which is why International Biotechnology Trust, a London-listed closed-end fund, may appeal to those seeking a lower-risk entry to this high-risk niche. First, it provides diversification, spreading its bets between 58 companies, rather than one. Second, only 10 per cent of IBT's funds are invested in the perenially underperforming UK - much of them in Shire, a long-term holding. Instead, it has 80 per cent of its capital in the US, where it is exposed to both the sector's stalwarts, such as Amgen and Genzyme, and up-and-coming mid-caps that might pass the amateur by - Micromet, the cancer specialist that is its biggest holding, being a prime example. Finally, through its relationship with SV Life Science, IBT has 20 per cent of its £110 million portfolio tied up in unquoted companies, which private investors are unable to access. Yesterday's first-half figures show IBT continues to deliver increases in net asset value (NAV) - up 8 per cent to 164p in the six months to March 31. Helped by clarity over US healthcare reforms, and a Japanese hostile bid for OSI, one of its holdings, NAV has since risen further - to 178p. The case from here is that half a dozen of IBT's big American stocks, such as Celgene and Vertex, will report important trial results in 2010. Meanwhile, its unquoted portfolio is now of a suffient maturity to start providing an exit. Above all, American biotech stocks, at 14 times earnings, remain inexpensive - even more so given that, at 139¾p, IBT sits at a 22 per cent discount to NAV, and will benefit from sterling weakness. Buy.
davebowler
24/3/2010
13:41
still trading 40 odd p below nav
shiptoshaw
03/3/2010
13:11
This thread includes charts etc
davebowler
09/2/2010
13:12
http://www.internationalbiotrust.com/fact_sheets/2009/January%202010.pdf
davebowler
13/11/2008
12:09
romi2nikki1...........It is a puzzle why the IBT share price has not responded to the recent increase in NAV. The company has declared an objective of maintaining the discount at no greater than 8%. To that end, they have recently bought back 5% of the shares into treasury at 20% discount. In addition, they do not hedge currency. Ongoing depreciation of GBP against USD is offsetting significantly any fall in underlying US asset values. Two good reasons to expect a correction.
foster
12/11/2008
20:48
Discount seems wide on historical basis, and considerably wider than discount on the Frostrow Trust ( biog). Biog much more volatile range, whereas a steady widening IBT. Consider that it is because IBT holds much more unquoted, but as long been the case. Excellent detail on IBT site, much more detail on pipeline progression and cashburn of holdings.
romi2nikki1
23/1/2007
21:33
see http://www.investorwords.com/5431/C_shares.html seems A shares incur a buying fee, B shares a selling fee & C shares an ongoing charge - which I'd have thought applied to most IT's prospectus http://www.internationalbiotrust.com/press_releases/issue_equity.pdf esp end page 2, & 3 take it the C shares will be invested separately then the portfolios combined in ratio to the NAV's achieved can see the point of the offer to raise cash DYOR & NAI!!
gurp
16/1/2007
20:34
Can anybody help me .What is a C share?
21up
13/11/2006
09:34
unfortunately now at a slight premium to nav, small bios in vogue with large pharmas looking for new products
gurp
11/10/2006
17:56
Information needed.Is MW talking about IBT?Thanks
21up
10/10/2006
14:15
Still going up. Was going to dump this one, but now hanging on!
duden1
04/10/2006
21:13
I've noticed that whilst my miners and oils are bombing all my biotechs are ticking up from a very bad slump. I reckon IBT is pretty safe - probably won't be spectacular either up or down. cheerio pg
planetgong
04/10/2006
20:29
My daughter's wedding has been & gone,got a few quid spare,is IBT a good bet?
21up
01/9/2006
14:31
see IBT is starting an upward move presumably on the news of the use of genetically modified imune cells to fight skin cancer.
rogerl
05/5/2006
22:24
No mention of IBT on Mike Walters - different Investment trust entirely!
anakin54321
05/5/2006
22:08
Without sounding to cheeky,i take it Michael Walters has just posted something on IBT.Does anybody know what it says?Thanks
21up
03/5/2006
11:22
thanks fickena,hadnt shown on watchlist.
j4ckthehat
Chat Pages: Latest  8  7  6  5  4  3  2  1
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190717 08:38:21